US › Healthcare

Whitehawk Therapeutics, Inc. (WHWK)

US · Healthcare · Biotechnology

$4.08+0.99%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-16.6M

EPS

$-0.20

EPS estimate

$-0.30

EPS came in at -0.20 against a street estimate of -0.30 — a beat of 33.3%.

Key statistics

Market cap

$234.3M

Forward P/E

2.7

P/B

1.28

Book value

$2.46

EPS (TTM)

$-1.21

52-week high

$5.50

52-week low

$1.80

50-day MA

$4.28

200-day MA

$3.65

Beta

0.81

Analyst view

Analysts rate Whitehawk Therapeutics, Inc. a hold (0 buy, 3 hold, 0 sell out of 3) with an average price target of $7.50.

Shareholding

Insiders

12.62%

Institutions

80.94%

Largest institutional holders

Fund	Stake
Longwood Capital Partners LLC	8.22%
Qvt Financial LP	8.10%
Orbimed Advisors LLC	7.31%
Suvretta Capital Management, LLC	6.49%
venBio Select Advisor LLC	5.00%
KVP Capital Advisors, LP	3.80%
Siren, L.L.C.	3.65%
Yu Fan	3.63%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Whitehawk Therapeutics, Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.